Treatment selection for first‐line metastatic renal cell carcinoma in Australia: Impact of new therapy options-Reference-Cited by-同舟云学术

Treatment selection for first‐line metastatic renal cell carcinoma in Australia: Impact of new therapy options

Published:2019-11 Issue:S10 Volume:15 Page:3-10
ISSN:1743-7555
Container-title:Asia-Pacific Journal of Clinical Oncology
language:en
Short-container-title:Asia‐Pac J Clin Oncol

Author:

Schmidt Andrew¹,Azad Arun²,Goh Jeffrey³,Harris Carole⁴,Joshua Anthony M.⁵,Weickhardt Andrew⁶,Krieger Laurence⁷

Affiliation:

1. Liz Plummer Cancer Centre Cairns Queensland Australia

2. Peter McCallum Cancer Centre Melbourne Victoria Australia

3. Royal Brisbane and Women's Hospital, Butterfield StreetHerston & University of Queensland St Lucia Queensland Australia

4. St George Hospital and Sutherland Clinical School UNSW Kogarah New South Wales Australia

5. The Kinghorn Cancer Centre Darlinghurst New South Wales Australia

6. Olivia Newton‐John Cancer Research Institute Heidelberg Victoria Australia

7. Royal North Shore Hospital, Reserve Rd, St LeonardsNorthern Cancer Institute St. Leonards New South Wales Australia

Funder

Novartis Pharmaceuticals Australia

Publisher

Wiley

Subject

Oncology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/ajco.13289

Reference52 articles.

1. Drug utilisation sub‐committee (DUSC). Pazopanib and sunitinib for renal cell carcinoma: analysis of predicted versus actual utilisation.2014.http://www.pbs.gov.au/industry/listing/participants/public-release-docs/pazopanib-sunitinib/pazopanib-sunitinib.pdf. Accessed July 25 2019.

2. Renal cell carcinoma

3. Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

4. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management;Current Treatment Options in Oncology;2022-03-22

2. Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study;BMC Cancer;2021-01-05

3. Construction and Validation of a Convenient Clinical Nomogram to Predict the Risk of Brain Metastasis in Renal Cell Carcinoma Patients;BioMed Research International;2020-11-17